Adverse reactions
headache, fatigue, pain
ADVERSE REACTIONS, ADVERSE REACTION, INDURATION
A total of 125 (46.5%) of the 269 participants reported at least one adverse reaction within 28 days of either vaccination, of which 78 participants were in the CoronaVac group and 47 participants were in the control group. In addition, 74 (55.2%) of the 134 participants aged 1859 years reported adverse reactions, which was higher than the percentage of participants aged 60 years or older (51 of 135, 37.8%) (p=0.004).All adverse reactions were grade 1 (42.8%) or grade 2 (3.7%) and the most common adverse reactions were injection site pain (28.5% in the CoronaVac group and 36.7% in the control group) and fatigue (6.1% in the CoronaVac group and 8.9% in the control group). There were no significant differences in the percentages of participants with any adverse reaction between the CoronaVac and the control group and between the two subgroups within the same age population. For the CoronaVac group, there were only three cases of grade 2, one case of induration at the vaccination site in participants aged 18–59 years, one case of pain at the vaccination site and one case of headache in participants aged 60 years or older (Local and systemic solicited adverse reactions reported for 28 days after either vaccination. 